Kensington Investment Counsel’s Quest Diagnostics DGX Stock Holding History

Kensington Investment Counsel’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,419	Closed	-$340K	–	101
2023 Q2	$340K	Sell	2,419 -193	-7%	-$26.6K	0.22%	93
2023 Q1	$370K	Sell	2,612 -183	-7%	-$26.2K	0.28%	77
2022 Q4	$437K	Sell	2,795 -174	-6%	-$25K	0.34%	72
2022 Q3	$364K	Hold	2,969	–	–	0.31%	77
2022 Q2	$395K	Sell	2,969 -96	-3%	-$13.1K	0.34%	74
2022 Q1	$419K	Hold	3,065	–	–	0.28%	83
2021 Q4	$530K	Buy	+3,065	New	+$466K	0.31%	83
2021 Q2	$423K	Buy	3,209 +122	+4%	+$16K	0.29%	81
2021 Q1	$396K	Buy	3,087 +71	+2%	+$8.75K	0.3%	81
2020 Q4	$359K	Buy	+3,016	New	+$368K	0.3%	81

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kensington Investment Counsel's DGX Position: Q3 2023 in Review

Kensington Investment Counsel sold out of Quest Diagnostics (DGX) in Q3 2023, closing a stake of 2,419 shares — an estimated $340K sold.

Kensington Investment Counsel first reported a position in DGX in Q4 2020 and held it in 10 quarters. The position peaked at $530K in Q4 2021. 795 funds tracked by Wall St. Rank hold DGX as of Q3 2023.

Kensington Investment Counsel reported no remaining Quest Diagnostics position as of Q3 2023 after selling out during the quarter.
Kensington Investment Counsel sold 2,419 Quest Diagnostics shares in Q3 2023, an estimated $340K.
Kensington Investment Counsel first reported a position in Quest Diagnostics in Q4 2020 and held it in 10 quarters.
Kensington Investment Counsel's Quest Diagnostics position peaked at $530K in Q4 2021.
795 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2023.

Based on Kensington Investment Counsel's 13F filing for Q3 2023, filed 9 Nov 2023.